| Infliximab for induction and maintenance therapy for ulcerative colitis P Rutgeerts, WJ Sandborn, BG Feagan, W Reinisch, A Olson, J Johanns, ... New England Journal of Medicine 353 (23), 2462-2476, 2005 | 4877 | 2005 |
| Infliximab for the treatment of fistulas in patients with Crohn's disease DH Present, P Rutgeerts, S Targan, SB Hanauer, L Mayer, ... New England Journal of Medicine 340 (18), 1398-1405, 1999 | 3528 | 1999 |
| Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment XC Morgan, TL Tickle, H Sokol, D Gevers, KL Devaney, DV Ward, ... Genome biology 13, 1-18, 2012 | 3037 | 2012 |
| Infliximab maintenance therapy for fistulizing Crohn's disease BE Sands, FH Anderson, CN Bernstein, WY Chey, BG Feagan, ... New England Journal of Medicine 350 (9), 876-885, 2004 | 2846 | 2004 |
| Vedolizumab as induction and maintenance therapy for ulcerative colitis BG Feagan, P Rutgeerts, BE Sands, S Hanauer, JF Colombel, ... New England Journal of Medicine 369 (8), 699-710, 2013 | 2839 | 2013 |
| Vedolizumab as induction and maintenance therapy for Crohn's disease WJ Sandborn, BG Feagan, P Rutgeerts, S Hanauer, JF Colombel, ... New England Journal of Medicine 369 (8), 711-721, 2013 | 2488 | 2013 |
| Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target L Peyrin-Biroulet, W Sandborn, BE Sands, W Reinisch, W Bemelman, ... Official journal of the American College of Gastroenterology| ACG 110 (9 …, 2015 | 1976 | 2015 |
| Ustekinumab as induction and maintenance therapy for Crohn’s disease BG Feagan, WJ Sandborn, C Gasink, D Jacobstein, Y Lang, JR Friedman, ... New England journal of medicine 375 (20), 1946-1960, 2016 | 1958 | 2016 |
| Tofacitinib as induction and maintenance therapy for ulcerative colitis WJ Sandborn, C Su, BE Sands, GR D’Haens, S Vermeire, S Schreiber, ... New England Journal of Medicine 376 (18), 1723-1736, 2017 | 1880 | 2017 |
| STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD … D Turner, A Ricciuto, A Lewis, F D’amico, J Dhaliwal, AM Griffiths, ... Gastroenterology 160 (5), 1570-1583, 2021 | 1859 | 2021 |
| Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial W Hueber, BE Sands, S Lewitzky, M Vandemeulebroecke, W Reinisch, ... Gut 61 (12), 1693-1700, 2012 | 1632 | 2012 |
| ACG clinical guideline: management of Crohn's disease in adults GR Lichtenstein, EV Loftus, KL Isaacs, MD Regueiro, LB Gerson, ... Official journal of the American College of Gastroenterology| ACG 113 (4 …, 2018 | 1482 | 2018 |
| Ustekinumab induction and maintenance therapy in refractory Crohn's disease WJ Sandborn, C Gasink, LL Gao, MA Blank, J Johanns, C Guzzo, ... New England Journal of Medicine 367 (16), 1519-1528, 2012 | 1308 | 2012 |
| Management of Crohn's disease in adults GR Lichtenstein, SB Hanauer, WJ Sandborn, ... Official journal of the American College of Gastroenterology| ACG 104 (2 …, 2009 | 1298 | 2009 |
| Ustekinumab as induction and maintenance therapy for ulcerative colitis BE Sands, WJ Sandborn, R Panaccione, CD O’Brien, H Zhang, J Johanns, ... New England Journal of Medicine 381 (13), 1201-1214, 2019 | 1172 | 2019 |
| Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis JF Colombel, P Rutgeerts, W Reinisch, D Esser, Y Wang, Y Lang, ... Gastroenterology 141 (4), 1194-1201, 2011 | 1069 | 2011 |
| The safety of vedolizumab for ulcerative colitis and Crohn's disease JF Colombel, BE Sands, P Rutgeerts, W Sandborn, S Danese, G D'Haens, ... Gut 66 (5), 839-851, 2017 | 911 | 2017 |
| Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed BE Sands, BG Feagan, P Rutgeerts, JF Colombel, WJ Sandborn, R Sy, ... Gastroenterology 147 (3), 618-627. e3, 2014 | 851 | 2014 |
| Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis BE Sands, L Peyrin-Biroulet, EV Loftus Jr, S Danese, JF Colombel, ... New England Journal of Medicine 381 (13), 1215-1226, 2019 | 744 | 2019 |
| Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease GR Lichtenstein, S Yan, M Bala, M Blank, BE Sands Gastroenterology 128 (4), 862-869, 2005 | 740 | 2005 |
